Why the study?
Does mRNA-1273 given as a 2 dose-regimen improve immune responses to SARS-CoV-2 in participants 18 years and older?
Does mRNA-1273 given as a 2 dose-regimen improve immune responses to SARS-CoV-2 in participants 18 years and older?
The mRNA-1273 vaccine at 50 and 100 µg doses is safe and immunogenic in adults.
Answers are grounded in this paper and cite their sources.
Supports mRNA-1273 in adults; extends equivocal data from 2 prior small studies.
Vaccination with mRNA-1273 resulted in significant immune responses to SARS-CoV-2 in participants 18 years and older, with an acceptable safety profile, confirming the safety and immunogenicity of 50 and 100 µg mRNA-1273 given as a 2 dose-regimen. ClinicalTrials.gov; NCT04405076.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: